1921
Volume 96, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

The World Health Organization's (WHO) recommendation is 28-day course of meglumine antimoniate (Glucantime, Sanofi Aventis, France) for the treatment of visceral leishmaniasis (VL). The aim of this study was to evaluate the effectiveness of a shorter duration of treatment in regions with low level of resistance to Glucantime. During 13 years, this study was conducted in three phases on 392 patients. In the pilot first phase, we performed splenic punctures in seven patients to assess the correlation between the changes in the parasite load during treatment with Glucantime and defervescence. With defervescence, parasite density was dramatically dropped ( = 0.014), propounding defervescence as a marker of parasitological response. On the basis of the results, we conducted a randomized trial on 75 patients, comparing the efficacy of continuation of Glucantime therapy for 1, 2, or 3 weeks after defervescence. The treatment course of 1 week after defervescence (mean = 11.7 days) was non-inferior to that of 3 weeks (final cure rate, 96% versus 100%; = 0.023). The third phase was a retrospective cohort study of 302 patients treated either with the WHO's regimen or for 7 days after defervescence (intervention group). Relapse was detected in 8.3% patients of the intervention group and in 5% patients following the WHO's regimen ( = 0.006 for non-inferiority). The final duration of treatment in intervention group was significantly shorter than standard course (13.3 ± 2.6 versus 28 days; < 0.001). In summary, treatment of VL with Glucantime for 1 week after defervescence was non-inferior to and appears to be an acceptable alternative to the standard 28-day course for patients in Iran who show a response to antimonial therapy.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.16-0345
2017-01-11
2019-05-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/1/182.html?itemId=/content/journals/10.4269/ajtmh.16-0345&mimeType=html&fmt=ahah

References

  1. Murray HW, Berman JD, Davies CR, Saravia NG, , 2005. Advances in leishmaniasis. Lancet 366: 15611577.[Crossref] [Google Scholar]
  2. Alborzi A, Pouladfar GR, Aelami MH, , 2007. Visceral leishmaniasis; literature review and Iranian experience. Iran J Clinic Infect Dis 2: 99108. [Google Scholar]
  3. Alborzi A, Rasouli M, Shamsizadeh A, , 2006. Leishmania tropica-isolated patient with visceral leishmaniasis in southern Iran. Am J Trop Med Hyg 74: 306307. [Google Scholar]
  4. Magill AJ, Grogl M, Gasser RA, Sun W, Oster CN, , 1993. Visceral infection caused by Leishmania tropica in veterans of operation desert storm. N Engl J Med 328: 13831387.[Crossref] [Google Scholar]
  5. Karamian M, Motazedian MH, Mehrabani D, Gholami K, , 2007. Leishmania major infection in a patient with visceral leishmaniasis: treatment with Amphotericin B. Parasitol Res 101: 14311434.[Crossref] [Google Scholar]
  6. Alborzi A, Pouladfar GR, Moghadam AG, Attar A, Drakhshan N, Khosravi Maharlooei M, Kalantari M, , 2013. First molecular-based detection of mucocutaneous leishmaniasis caused by Leishmania major in Iran. J Infect Dev Ctries 7: 413416.[Crossref] [Google Scholar]
  7. Mandal G, Mandal S, Sharma M, Charret KS, Papadopoulou B, Bhattacharjee H, Mukhopadhyay R, , 2015. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1. PLoS Negl Trop Dis 9: e0003500.[Crossref] [Google Scholar]
  8. Berman J, , 2015. Amphotericin B formulations and other drugs for visceral leishmaniasis. Am J Trop Med Hyg 92: 471473.[Crossref] [Google Scholar]
  9. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, , 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 11041106.[Crossref] [Google Scholar]
  10. WHO, 1982. Report of the Informal Meeting on the Chemotherapy of Visceral Leishmaniasis. TDR/CHEMLEISH/VL/82.3. [Google Scholar]
  11. Chulav JD, Bhatt SM, , 1983. A comparison of 3 dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. J Infect Dis 148: 148155.[Crossref] [Google Scholar]
  12. Sundar S, Reed SG, Singh VP, Kumar CKP, Murray HW, , 1998. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 351: 563565.[Crossref] [Google Scholar]
  13. Alborzi A, Rasouli M, Nademi Z, Kadivar MR, Pourabbas B, , 2006. Evaluation of rK39 strip test for the diagnosis of visceral leishmaniasis in infants. East Mediterr Health J 12: 294299. [Google Scholar]
  14. Kadivar MR, Kajbaf TZ, Karimi A, Alborzi A, , 2000. Childhood visceral leishmaniasis complicated by bacterial infections. East Mediterr Health J 6: 879883. [Google Scholar]
  15. Kirk R, Sati MH, , 1947. Observation on the use of sodium antimony gluconte (sodium stibogluconate) in treatment of kala-azar. Ann Trop Med Parasitol 41: 1421.[Crossref] [Google Scholar]
  16. Leng YJ, , 1982. A review of kala-azar in China from 1949–1959. Trans R Trop Med Hyg 76: 531537.[Crossref] [Google Scholar]
  17. Copeland NK, Aronson NE, , 2015. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis 28: 426437.[Crossref] [Google Scholar]
  18. Croft SL, Coombs GH, , 2003. Leishmaniasis current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502508.[Crossref] [Google Scholar]
  19. Wigers DJB, , 1971. A ten year study of kala-azar in Tharke (Meru District Kenya) relapses. East Afr Med J 48: 551558. [Google Scholar]
  20. Jamil KM, Haque R, Rahman R, Faiz MA, Bhuiyan AT, Kumar A, Hassan SM, Kelly H, Dhalaria P, Kochhar S, Desjeux P, Bhuiyan MA, Khan MM, Ghosh RS, , 2015. Effectiveness study of paromomycin IM injection (PMIM) for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis 9: e0004118.[Crossref] [Google Scholar]
  21. Sundar S, Pandey K, Thakur CP, Jha TK, Das VN, Verma N, Lal CS, Verma D, Alam S, Das P, , 2014. Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study. PLoS Negl Trop Dis 8: e3169.[Crossref] [Google Scholar]
  22. Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B, , 2014. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Glob Health 2: e51e57.[Crossref] [Google Scholar]
  23. Maintz EM, Hassan M, Huda MM, Ghosh D, Hossain MS, Alim A, Kroeger A, Arana B, Mondal D, , 2014. Introducing single dose liposomal amphotericin B for the treatment of visceral leishmaniasis in rural bangladesh: feasibility and acceptance to patients and health staff. J Trop Med 2014: 676817.[Crossref] [Google Scholar]
  24. Lucero E, Collin SM, Gomes S, Akter F, Asad A, Kumar Das A, Ritmeijer K, , 2015. Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS Negl Trop Dis 9: e0003699.[Crossref] [Google Scholar]
  25. Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, Hailu W, Abuzaid AA, Dorlo TP, Hurissa Z, Yifru S, Haleke W, Smith PG, Ellis S, Balasegaram M, El-Hassan AM, Schoone GJ, Wasunna M, Kimutai R, Edwards T, Hailu A, , 2014. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis 8: e2613.[Crossref] [Google Scholar]
  26. Pourabbas B, Ghadimi Moghadam A, Pouladfar G, Rezaee Z, Alborzi A, , 2013. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis. Am J Trop Med Hyg 88: 868871.[Crossref] [Google Scholar]
  27. Nyakundi PM, Wasunna KM, Rashid Jr, Gachihi GS, Mbugua J, Kirigi G, Muttunga J, , 1994. Is one year follow up justified in kala-azar post-treatment? East Afr Med J 71: 453459. [Google Scholar]
  28. Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, Ali N, , 2006. Immune responses in kala-azar. Indian J Med Res 123: 245266. [Google Scholar]
  29. Sudarshan M, Singh T, Chakravarty J, Sundar S, , 2015. A correlative study of splenic parasite score and peripheral blood parasite load estimation by qPCR in visceral leishmaniasis. J Clin Microbiol 53: 39053907.[Crossref] [Google Scholar]
  30. Aikat BK, Sahaya S, Pathania AG, Bhattacharya PK, Desai N, Prasad LS, Mishra S, Jain S, , 1979. Clinical profile of cases of kala-azar in Bihar. Indian J Med Res 70: 563570. [Google Scholar]
  31. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, , 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 11041107.[Crossref] [Google Scholar]
  32. Coura-Vital W, Araújo VE, Reis IA, Amancio FF, Reis AB, Carneiro M, , 2014. Prognostic factors and scoring system for death from visceral leishmaniasis: an historical cohort study in Brazil. PLoS Negl Trop Dis 8: e3374.[Crossref] [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0345
Loading
/content/journals/10.4269/ajtmh.16-0345
Loading

Data & Media loading...

  • Received : 01 May 2016
  • Accepted : 06 Sep 2016
  • Published online : 11 Jan 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error